Commentary on: The optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical Practice

Authors Information
Article Notes and Dates
To Cite : El-Shabrawi M, Isa M. Commentary on: The optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical Practice, Hepat Mon. 2013 ;13(2):e7867. doi: 10.5812/hepatmon.7867.
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
This article has a relationship commentary-article with this article : The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice
  • 1. Abenavoli L, Mazza M, Almasio PL. The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C. Hepat Mon. 2011; 11(4): 240-6[PubMed]
  • 2. Poynard Thierry, Yuen Man-Fung, Ratzin Vlad, Lai Ching Lung. Viral hepatitis C. The Lancet. 2003; 362(9401): 2095-100[DOI]
  • 3. Abonyi ME, Lakatos PL. Ribavirin in the treatment of hepatitis C. Anticancer Res. 2005; 25(2B): 1315-20[PubMed]
  • 4. Weber George, Shen Fei, Prajda Noemi, Abonyi Margit. Down-regulation by drugs of the increased signal transduction in cancer cells. Advances in Enzyme Regulation. 2000; 40(1): 19-34[DOI]
  • 5. Jamall IS, Yusuf S, Azhar M, Jamall S. Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3? World J Gastroenterol. 2008; 14(43): 6627-31[PubMed]
  • 6. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004; 40(6): 993-9[DOI][PubMed]
  • 7. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003; 38(3): 639-44[DOI][PubMed]
  • 8. Bjoro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol. 2002; 37(2): 226-32[PubMed]
  • 9. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004; 40(3): 484-90[DOI][PubMed]
  • 10. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003; 38(1): 75-85[DOI][PubMed]
  • 11. Patel K, McHutchison JG. Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve Clin J Med. 2004; 71 Suppl 3-12[PubMed]
  • 12. Saleem N, Mubarik A, Qureshi AH, Siddiq M, Ahmad M, Afzal S, et al. Is there a correlation between degree of viremia and liver histology in chronic hepatitis C? J Pak Med Assoc. 2004; 54(9): 476-9[PubMed]
  • 13. Sikorska K, Stalke P, Izycka-Swieszewska E, Romanowski T, Bielawski KP. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. Med Sci Monit. 2010; 16(3)-43[PubMed]
  • 14. Sokal EM, Bourgois A, Stephenne X, Silveira T, Porta G, Gardovska D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol. 2010; 52(6): 827-31[DOI][PubMed]
  • 15. Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol. 2010; 52(4): 501-7[DOI][PubMed]
  • 16. Karnsakul W, Alford MK, Schwarz KB. Managing pediatric hepatitis C: current and emerging treatment options. Ther Clin Risk Manag. 2009; 2009(5): 651-60
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check